Targeting HIF-1 alpha transcriptional activity drives cytotoxic immune effector cells into melanoma and improves combination immunotherapy
Open accessThe DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
Hypoxia is a key factor responsible for the failure of therapeutic response in most solid tumors and promotes the acquisition of tumor resistance to various antitumor immune effectors. Reshaping the hypoxic immune suppressive tumor microenvironment to improve cancer immunotherapy is still a relevant challenge. We investigated the impact of inhibiting HIF-1α transcriptional activity on cytotoxic immune cell infiltration into B16-F10 melanoma. We showed that tumors expressing a deleted form of HIF-1α displayed increased levels of NK and CD8+effector T cells in the tumor microenvironment, which was associated with high levels of CCL2 and CCL5 chemokines. We showed that combining acriflavine, reported as a pharmacological agent preventing HIF-1α/HIF-1β dimerization, dramatically improved the benefit of cancer immunotherapy based on TRP-2 peptide vaccination and anti-PD-1 blocking antibody. In melanoma patients, we revealed that tumors exhibiting high CCL5 are less hypoxic, and displayed high NK, CD3+, CD4+and CD8+T cell markers than those having low CCL5. In addition, melanoma patients with high CCL5 in their tumors survive better than those having low CCL5. This study provides the pre-clinical proof of concept for a novel triple combination strategy including blocking HIF-1α transcription activity along vaccination and PD-1 blocking immunotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


![Fig. 3 The infiltration of NK and CD8+ T cells into HIF-1α Del tumors is associated with the release of CCL5 from tumor cells. A Tumor growth curves of HIF-1α (FL) and HIF-1α (Del) B16-F10 cells transplanted in C57BL/6 mice untreated (Isotype) or treated with NK-depleting antibody (anti-NK1.1). Mice were injected intraperitoneally with 200 µg of Isotype or anti-NK1.1 three days before the engraftment tumor cells and at days 0, 4, 8, 11, 15, 18 and 22 after the engraftment. Results are reported as average of 10 mice per group for [HIF-1α (FL) + Isotype] and [HIF-1α (Del) + anti-NK] groups, and 8 mice per group for [HIF-1α (Del) + Isotype] group. Error bars represent mean ± SEM. ns = not significant, * = p < 0.05, ** = p < 0.01 and *** = p < 0.001 determined by unpaired two tailed Student’s t test. B Tumor growth curves of HIF-1α (FL) and HIF-1α (Del) B16-F10 cells transplanted in untreated (Isotype) or CD8a-depleted (anti-CD8a) C57BL/6 mice. Mice were injected intraperitoneally with 200 µg of Isotype or anti-CD8a antibody three days before the engraftment tumor cells and at days 0, 4, 8, 11, 15, 18 and 22 after the engraftment. Data are reported as average of 8 mice per group for [HIF-1α (FL) + Isotype] group, 5 mice per group for [HIF-1α (Del)+ Isotype] and 7 mice per group for [HIF-1α (Del)+ anti-CD8]. Error bars represent mean ± SEM. ns = not significant, ** = p < 0.01 and *** = p < 0.001 determined by unpaired one tailed Student’s t test. C Cytokines/chemokines profiling in tumor lysate of HIF-1α (FL) and HIF-1α (Del)B16-F10 tumors using Mouse XL Cytokine Array. Left panel: Cytokines/chemokines up- and down-regulated in HIF-1α (Del) compared to HIF-1α (FL) B16-F10 tumor are highlighted in red and in green, respectively. Right panel: signal ratio of HIF-1α Del/HIF-1α FL (Del/FL). Mouse XL Cytokine Array for cytokines/chemokines profiling was performed once. D ELISA quantification of CCL2 and CCL5 in tumor plasma of HIF-1α (FL)and HIF-1α (Del)B16-F10 tumors. Data are reported in pg/ml/g of tumor. Bars represent an average of 8 mice. Error bars represent mean ± SEM. ** = p < 0.01 determined by unpaired two tailed Student’s t test. E ELISA quantification of CCL2 and CCL5 released in the supernatant of HIF-1α (FL) and HIF-1α (Del) B16-F10 cells cultured under normoxia (21% pO2, N) or hypoxia (0.1% pO2, H) conditions for 24 h. Bars are mean ± SEM from three independent experiments. ns = not significant, *** = p < 0.001 determined by unpaired two tailed Student’s t test. F Immunohistochemical staining of CCL5 (red) performed on HIF-1α (FL)and HIF-1α (Del) B16-F10 tumors. Scale bars: 200 μm.](https://figures.cochat.ai/paper-figures/affe15fd51894254b39971430692787e/targeting-hif-1-alpha-transcriptional-activity-drives-cytotoxic-immune-effector-figure-3.jpg)

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In follicular thyroid cancer, loss of HIF-1α reduces PD-L1 expression on tumor cells, resulting in reduced tumor growth, and in glioma, expression of PD-L1 strongly correlated with HIF-1α levels, and high PD-L1 was associated with worse outcome [71,72].”
From Revisiting the HIF switch in the tumor and its immune microenvironment. (2022) · cites this paper as [72]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Thus, HIF-1/2α inhibition in mouse models of cancer promotes the efficacy of anti-PD1 therapy and increases infiltration of cytotoxic immune effector cells [84–86].”
From The HIF Axes in Cancer - Angiogenesis, Metabolism and Immune-Modulation (2025) · cites this paper as [85]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Acriflavine treatment of tumor-bearing mice was recently reported to increase intratumoral CD8+ T cells and NK cells (42, 43).”
From HIF inhibitor 32-134D eradicates murine hepatocellular carcinoma in combination with anti-PD1 therapy (2022) · cites this paper as [43]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“In follicular thyroid cancer, loss of HIF-1α reduces PD-L1 expression on tumor cells, resulting in reduced tumor growth, and in glioma, expression of PD-L1 strongly correlated with HIF-1α levels, and high PD-L1 was associated with worse outcome [71,72].”
From Revisiting the HIF switch in the tumor and its immune microenvironment. (2022) · cites this paper as [72]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“In follicular thyroid cancer, loss of HIF-1α reduces PD-L1 expression on tumor cells, resulting in reduced tumor growth, and in glioma, expression of PD-L1 strongly correlated with HIF-1α levels, and high PD-L1 was associated with worse outcome [71,72].”
From Revisiting the HIF switch in the tumor and its immune microenvironment. (2022) · cites this paper as [72]
Experimental — accuracy not yet measured
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
RETRACTED: Acriflavine inhibits HIF-1 dimerization, tumor growth, and vascularization
Lee, K., Zhang, H., Qian, D. Z., Rey, S., Liu, J. O., & Semenza, G. L. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0909353106 · Cited by 451 · cited 1×
“ACF pretreatment in mice bearing prostate cancer xenografts decreased tumor growth and inhibited vascularization [21].”
BackgroundRetractedTargeting HIF-1 for cancer therapy
Semenza, G. L. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1187 · Cited by 6,717 · cited 1×
“HypoxiaInducible Factor-1 alpha (HIF-1α) is the major factor mediating the adaptive response to changes in tissue oxygen level [3].”
BackgroundGenomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma
Hugo, W., Zaretsky, J. M., Sun, L., Song, C., Moreno, B. H., Hu-Lieskovan, S., Berent-Maoz, B., Pang, J., Chmielowski, B., Cherry, G., et al. (2016) · Cell · doi:10.1016/j.cell.2016.02.065 · Cited by 3,448
Noman, M. Z., Desantis, G., Janji, B., Hasmim, M., Karray, S., Dessen, P., Bronte, V., & Chouaib, S. (2014) · Journal of Experimental Medicine · doi:10.1084/jem.20131916 · Cited by 2,166
Self-citationDefining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics
Semenza, G. L. (2010) · Oncogene · doi:10.1038/onc.2009.441 · Cited by 1,712 · cited 1×
“to activate the expression of several genes involved in various biological processes [4].”
BackgroundHypoxia-inducible factors: mediators of cancer progression and targets for cancer therapy
Semenza, G. L. (2012) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2012.01.005 · Cited by 1,514
Defining normoxia, physoxia and hypoxia in tumours—implications for treatment response
McKeown, S. R. (2014) · The British Journal of Radiology · doi:10.1259/bjr.20130676 · Cited by 1,050 · cited 1×
“Most solid tumors are hypoxic and characterized by the presence of poorly oxygenated areas (pO2 pressure less than 8 mmHg) [1].”
BackgroundA mechanism of hypoxia-mediated escape from adaptive immunity in cancer cells
Barsoum, I. B., Smallwood, C. A., Siemens, D. R., & Graham, C. H. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-0992 · Cited by 767
Digoxin and other cardiac glycosides inhibit HIF-1α synthesis and block tumor growth
Zhang, H., Qian, D. Z., Tan, Y. S., Lee, K., Gao, P., Ren, Y. R., Rey, S., Hammers, H., Chang, D., Pili, R., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0809763105 · Cited by 624 · cited 1×
“Digoxin and other cardiac glycosides that inhibit HIF-1α protein synthesis blocked tumor growth [22].”
BackgroundTumour hypoxia, chemotherapeutic resistance and hypoxia-related therapies
Shannon, A. M., Bouchier-Hayes, D. J., Condron, C. M., & Toomey, D. (2003) · Cancer Treatment Reviews · doi:10.1016/s0305-7372(03)00003-3 · Cited by 559 · cited 1×
“Hypoxia contributes to the failure of conventional cancer therapies such as chemotherapy [5] and radiation therapy [6], while data underlining its real impact on immunotherapy efficacy are still missing.”
Background
Cited by
Mechanisms driving the immunoregulatory function of cancer cells
van Weverwijk, A., & de Visser, K. E. (2023) · Nature Reviews Cancer · doi:10.1038/s41568-022-00544-4 · Cited by 272
Metabolic reprogramming and therapeutic resistance in primary and metastatic breast cancer
Liu, S., Zhang, X., Wang, W., Li, X., Sun, X., Zhao, Y., Wang, Q., Li, Y., Hu, F., & Ren, H. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02165-x · Cited by 246
Revisiting the HIF switch in the tumor and its immune microenvironment.
Cowman, S. J., & Koh, M. Y. (2022) · Trends in Cancer · doi:10.1016/j.trecan.2021.10.004 · Cited by 256
Targeting oncogene and non-oncogene addiction to inflame the tumour microenvironment
Petroni, G., Buqué, A., Coussens, L. M., & Galluzzi, L. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00415-5 · Cited by 160
Bigos, K. J. A., Quiles, C. G., Lunj, S., Smith, D. J., Krause, M., Troost, E. G. C., West, C., Hoskin, P., & Choudhury, A. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1331355 · Cited by 166
Metadata
- Authors
- Lequeux, A., Noman, M. Z., Xiao, M., Van Moer, K., Hasmim, M., Benoit, A., Bosseler, M., Viry, E., Arakelian, T., Berchem, G., Chouaib, S., & Janji, B.
- Affiliations
- Luxembourg Institute of Health (LU)
- Centre Hospitalier de Luxembourg (LU)
- Corresponding author
- Janji, Bassam
- ORCID
- Venue
- Oncogene
- Published
- 2021-06-21
- Volume
- 40
- Issue
- 28
- Pages
- 4725-4735
- ISSN
- 0950-9232 (ISSN-L)
- 1476-5594
- PMC
- PMC8282500
- OpenAlex
- W3176619285
- Semantic Scholar
- 463b0c0c66926b7b48da95de23ffb093c5104bd6
- Cited by
- 129
- References
- 30
- Citations by year
- 2026: 9 · 2025: 25 · 2024: 28 · 2023: 25 · 2022: 34 · 2021: 8
- FWCI
- 9.28
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Oncogene (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- Fondation Cancer (FC/2018/06)
- Fonds National de la Recherche Luxembourg (PRIDE15/10675146/ CANBIO, 10675146, PRIDE 15/10675146/)
- Fonds De La Recherche Scientifique - FNRS (PRIDE15/10675146/CANBIO, 7.4606.18)
- Action LIONS Vaincre le Cancer
- Cilag
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- HIF-1α, hypoxia, melanoma, tumor immune microenvironment, natural killer cells, CD8+ T cells, RANTES, MCP-1, acriflavine, anti-PD-1 therapy, combination immunotherapy, tumor hypoxia, patient survival
- MeSH terms
- Animals, Humans, Immunotherapy, Killer Cells, Natural, Melanoma, Melanoma, Experimental, Mice, Inbred C57BL, CD8-Positive T-Lymphocytes, Chemokine CCL5, Cell Line, Tumor, Mice, Hypoxia-Inducible Factor 1, alpha Subunit, Tumor Microenvironment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Targeting HIF-1 alpha transcriptional activity drives cytotoxic immune effector cells into melanoma and improves combination immunotherapy. https://app.cochat.ai/papers/10.1038/s41388-021-01846-x
- The paper
- Lequeux, A., Noman, M. Z., Xiao, M., Van Moer, K., Hasmim, M., Benoit, A., Bosseler, M., Viry, E., Arakelian, T., Berchem, G., Chouaib, S., & Janji, B. (2021). Targeting HIF-1 alpha transcriptional activity drives cytotoxic immune effector cells into melanoma and improves combination immunotherapy. Oncogene. https://doi.org/10.1038/s41388-021-01846-x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.